(Q40672192)

22 September 2017

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck (English)

1 reference

metastatic squamous cell carcinoma

22 September 2017

0 references

1 reference

18

Herbst RS

1 reference

22 September 2017

Tseng JE

1

1 reference

22 September 2017

Glisson BS

2

1 reference

22 September 2017

Khuri FR

3

1 reference

22 September 2017

Shin DM

4

1 reference

22 September 2017

Myers JN

5

1 reference

22 September 2017

El-Naggar AK

6

1 reference

22 September 2017

Roach JS

7

1 reference

22 September 2017

Ginsberg LE

8

1 reference

22 September 2017

Thall PF

9

1 reference

22 September 2017

Wang X

10

1 reference

22 September 2017

Teddy S

11

1 reference

22 September 2017

Lawhorn KN

12

1 reference

22 September 2017

Zentgraf RE

13

1 reference

22 September 2017

Steinhaus GD

14

1 reference

22 September 2017

Pluda JM

15

1 reference

22 September 2017

Abbruzzese JL

16

1 reference

22 September 2017

Hong WK

17

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

22 September 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

22 September 2017

92

1 reference

22 September 2017

2364-2373

1 reference

22 September 2017

9

1 reference

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

22 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Thalidomide: current and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

The role of chemotherapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr1 in mouse colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Immunomodulation by thalidomide and thalidomide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Angiogenic Factors in Laryngeal Carcinomas: Do They Have Prognostic Relevance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011101%2992%3A9%3C2364%3A%3AAID-CNCR1584%3E3.0.CO%3B2-P

10.1002/1097-0142(20011101)92:9<2364::AID-CNCR1584>3.0.CO;2-P

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference